论文部分内容阅读
应用非巯基血管紧张素转换酶抑制剂（ＡＣＥＩ）——苯那普利治疗４０例慢性肾功能衰竭（ＣＲＦ）伴高血压患者，其中氮质血症期３０例，尿毒症期１０例，观察了治疗前后血压、肾功能的变化，并通过彩色多普勒超声诊断仪测定了ＣＲＦ患者治疗前后肾血管阻力指数（ＲＩ）的变化，结果显示：苯那普利治疗后两组收缩压和舒张压较治疗前均有明显下降（Ｐ＜０．０１）；氮质血症期患者ＲＩ值均较治疗前有明显下降（Ｐ＜０．０１），尿毒症期患者ＲＩ值治疗前后变化无显著性差异（Ｐ＞０．０５）。血清肌酐（Ｓｃｒ）、尿素氮（ＢＵＮ）、肌酐清除率（Ｃｃｒ）治疗前后亦无明显变化；治疗过程中未观察到明显副作用。说明苯那普利能有效地降低ＣＲＦ患者血压，降低氮质血症期患者ＲＩ值，进一步证实了苯那普利扩张肾血管，降低肾血管阻力，保护肾功能的作用，是治疗肾性高血压较理想的药物。
Forty patients with chronic renal failure (CRF) and hypertension were treated with ACEI-benazepril, including 30 cases of azotemia and 10 cases of uremia. The changes of blood pressure and renal function before and after treatment were measured. The changes of renal vascular resistance index (RI) before and after treatment were measured by color Doppler sonography. The results showed that systolic blood pressure and diastolic blood pressure (P <0.01). The RI of patients with azotemia was significantly lower than that of before treatment (P <0.01), while there was no significant difference between before and after treatment of RI in patients with uremia Sex differences (P> 0.05). Serum creatinine (Scr), blood urea nitrogen (BUN) and creatinine clearance (Ccr) had no significant changes before and after treatment; no obvious side effects were observed during the treatment. It is concluded that benazepril can effectively reduce the blood pressure in patients with CRF and reduce the RI in patients with azotemia, further confirming the effect of benazepril in expanding renal vessels, reducing renal vascular resistance and protecting renal function, Better blood pressure medication.